MEDP

SEC source: 0001567619-22-000729 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,483,019

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $216.175. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-22-000228 · doc1.xml · nonDerivative · entry 3

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,486,357

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $217.36. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-22-000224 · doc1.xml · nonDerivative · entry 3

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,486,357

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $217.36. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-22-000228 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,506,101

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $217.48 to $220.44. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-22-000224 · doc1.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,506,101

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $217.48 to $220.44. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-22-000228 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,519,170

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $218.835 to $222.14. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-22-000224 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,519,170

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $218.835 to $222.14. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-022666 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,536,546

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $217.635 to $221.125. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-022665 · doc1.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,536,546

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $217.635 to $221.125. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-022666 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,553,296

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $218.395 to $229.14. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-022665 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,553,296

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $218.395 to $229.14. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-022564 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,577,414

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $223.28 to $227.87. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-022563 · doc1.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,577,414

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $223.28 to $227.87. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-022564 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,616,585

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $219.94 to $224.68. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-022563 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,616,585

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $219.94 to $224.68. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-022495 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,639,415

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $217.08 to $222.00. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-022494 · doc1.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,639,415

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $217.08 to $222.00. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-022495 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,678,375

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.785 to $217.53. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-022494 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,678,375

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.785 to $217.53. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-022408 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,696,508

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $215.12. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-022407 · doc1.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,696,508

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $215.12. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-022408 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,719,242

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $215.64. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-022407 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,719,242

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $215.64. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-022252 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,749,847

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $211.175. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-022250 · doc1.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,749,847

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $211.175. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-022252 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,755,806

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $210.5425. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-022250 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,755,806

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $210.5425. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-021935 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,758,230

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $210.90. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-021934 · doc1.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,758,230

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $210.90. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-021935 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,758,539

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $213.455. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-021934 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,758,539

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $213.455. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-021832 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,773,533

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $214.46. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-021831 · doc1.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,773,533

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $214.46. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-021832 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,789,404

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $213.80. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-021831 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,789,404

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $213.80. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-021705 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,807,924

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.25 to $211.92. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-021704 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,807,924

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.25 to $211.92. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-021582 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,808,324

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $211.49. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-021580 · doc1.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,808,324

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $211.49. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-021582 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,814,414

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $214.80. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-021580 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,814,414

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $214.80. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-021383 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,841,056

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-021382 · doc1.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,841,056

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

SEC source: 0001567619-21-021383 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,841,253

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $214.345. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-021382 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,841,253

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $214.345. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-021226 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,853,368

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $214.27. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-021225 · doc1.xml · nonDerivative · entry 2

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,853,368

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $214.27. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-021226 · doc1.xml · nonDerivative · entry 1

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,868,439

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.25 to $214.86. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001567619-21-021225 · doc1.xml · nonDerivative · entry 1

Medpace Investors, LLC · CIK 0001524599 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,868,439

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2021.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.25 to $214.86. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

SEC source: 0001567619-21-021146 · doc1.xml · nonDerivative · entry 2

Troendle August J. · CIK 0001622058 · Director · CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Medpace Investors, LLC

Disclosed balance after: 5,883,017

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on November 1, 2021.

F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $210.00 to $221.11. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

F3 · ownership.nature: The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.